![Bernardus MacHielse](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Bernardus MacHielse
Direktor/Vorstandsmitglied bei REDWOOD HOLDING S.A.
Ursprung des Netzwerks ersten Grades von Bernardus MacHielse
Einheit | Art der Einheit | Industrie | |
---|---|---|---|
Polyneuron Pharmaceuticals AG
![]() Polyneuron Pharmaceuticals AG Pharmaceuticals: MajorHealth Technology Polyneuron Pharmaceuticals AG develops drugs for the treatment of autoimmune disorders. It develops drugs for the treatment of anti-MAG neuropathy disease and multifocal motor neuropathy disease. The firm also develops antibody-catch, a platform technology that enables the development of drugs for highly specific interception of autoimmune disease antibodies and focuses on autoimmune diseases of the peripheral nervous system that involve autoantibodies against carbohydrate epitopes. The company was founded by Andreas J. Steck, Beat Ernst, Pascal Hänggi and Ruben Herrendorffin in 2014 and is headquartered in Basel, Switzerland.
7
| Holding Company | Pharmaceuticals: Major | 7 |
Omthera Pharmaceuticals, Inc.
![]() Omthera Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Omthera Pharmaceuticals, Inc. operates as pharmaceuticals company which focuses on the clinical development of new therapies for dyslipidemia. The company was founded by Jerry Wisler and Michael Davidson in 2008 and is headquartered in Princeton, NJ.
6
| Subsidiary | Pharmaceuticals: Major | 6 |
F3 Platform Biologics, Inc.
![]() F3 Platform Biologics, Inc. BiotechnologyHealth Technology F3 Platform Biologics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of novel and practical biotechnology for human use. It handles research, clinical development, and commercialization of new indications surrounding amifostine, a compound that has been previously approved by FDA for indications involving the prevention and treatment of side effects related to cancer treatment and radiation therapy. The company was founded on June 5, 2018 and is headquartered in Atlanta, GA.
6
| Private Company | Biotechnology | 6 |
Private Company | Metal Fabrication | 2 |
Unternehmensgrafik - zweiten Grades
Beziehungen zu mehreren Unternehmen
Unternehmensverbindungen über das persönliche Netzwerk von Bernardus MacHielse
Unternehmen | Sektor | Verknüpfte Personen | Hauptposition |
---|---|---|---|
ABBOTT LABORATORIES | Medical Specialties | Corporate Officer/Principal Corporate Officer/Principal Corporate Officer/Principal | |
BRISTOL-MYERS SQUIBB COMPANY | Pharmaceuticals: Major | Sales & Marketing General Counsel | |
ImClone LLC
![]() ImClone LLC BiotechnologyHealth Technology ImClone LLC develops targeted biologic treatments designed for the medical needs of patients with tumors. The company was founded in 1984 and is headquartered in Bridgewater, NJ. | Biotechnology | General Counsel | |
JOHNSON & JOHNSON | Pharmaceuticals: Major | General Counsel | |
MedImmune LLC
![]() MedImmune LLC BiotechnologyHealth Technology MedImmune LLC develops medicines for the prevention and treatment of infectious diseases such as cancer and immune system disorders. It offers solutions in the areas of monoclonal antibodies and vaccines for infection, oncology, respiratory disease and inflammation, cardiovascular diseases, and neuroscience. The company was founded by Wayne T. Hockmeyer in 1988 and is headquartered in Gaithersburg, MD. | Biotechnology | Sales & Marketing Chief Executive Officer Corporate Officer/Principal Corporate Officer/Principal | |
STRYKER CORPORATION | Medical Specialties | Corporate Officer/Principal | |
ARIAD PHARMACEUTICALS, INC. | Biotechnology | Corporate Officer/Principal | |
Vicuron Pharmaceuticals LLC
![]() Vicuron Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Vicuron Pharmaceuticals LLC develops pharmaceutical products. It engages in discovering, developing, manufacturing, and commercializing vital medicine for seriously ill patients. The company offers anidulafungin drug, which prevents cell wall formation and other infectious fungi. It also offers antibiotic for the treatment of complicated skin and soft-tissue infections. The company was founded by Christopher T. Walsh in 1995 and is headquartered in King of Prussia, PA. | Pharmaceuticals: Major | Chief Executive Officer | |
OPTINOSE, INC. | Pharmaceuticals: Major | General Counsel | |
Dartmouth College | College/University | Undergraduate Degree Undergraduate Degree | |
Duke University
![]() Duke University Other Consumer ServicesConsumer Services Duke University is an academic university that offers undergraduate, graduate and professional programs. It also has publications and research services. The university was founded in 1838 and is headquartered in Durham, NC. | College/University | Undergraduate Degree | |
Index Ventures SA
![]() Index Ventures SA Investment ManagersFinance Index Ventures SA (Index Ventures) is a venture capital firm founded in 1996 by Neil Alexander Rimer, Gluseppe Zocco and Gerald Rimer. The firm is headquartered in Geneva, Switzerland. | Investment Managers | Corporate Officer/Principal | |
University of Southern California
![]() University of Southern California Other Consumer ServicesConsumer Services University of Southern California is a private research university that mainly offers undergraduate, graduate & other higher education. The university was founded in 1880 and is headquartered in Los Angeles, CA. | College/University | Undergraduate Degree | |
Sofinnova Partners SAS
![]() Sofinnova Partners SAS Investment ManagersFinance Sofinnova Partners SA (Sofinnova) is an independent venture capital firm established in 1972 and headquartered in Paris, France. Originally known as Sofinnova, the first venture capital firm created in France, the firm created a U.S. subsidiary in San Francisco in 1976. In 1997, both firms were bought out by their management teams, which become the majority shareholders of the new companies, Sofinnova Partners in Paris and Sofinnova Ventures in San Francisco. | Investment Managers | Private Equity Investor | |
Robert W. Baird & Co., Inc. (Broker)
![]() Robert W. Baird & Co., Inc. (Broker) Investment Banks/BrokersFinance Robert W. Baird & Co., Inc. (Broker) (Baird-Broker) is the broker-dealer division of Robert W. Baird & Co., Inc., an investment bank and financial services company headquartered in Milwaukee, Wisconsin. The firm was founded in 1919 and is ultimately owned by Baird Financial Group, Inc. Baird-Broker offers a full suite of comprehensive trading services for institutional clients. | Investment Banks/Brokers | Private Equity Analyst | |
ALNYLAM PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer | |
NEA Management Co. LLC
![]() NEA Management Co. LLC Investment ManagersFinance New Enterprise Associates LLC (New Enterprise Associates) is a venture capital firm founded in 1977. The firm headquartered in Menlo Park, California. | Investment Managers | Private Equity Investor Private Equity Investor | |
Northwestern University
![]() Northwestern University Other Consumer ServicesConsumer Services Northwestern University is a private institution founded in 1851 to serve the Northwest Territory, an area that now includes the states of Ohio, Indiana, Illinois, Michigan, Wisconsin and parts of Minnesota. Northwestern has three campuses | College/University | Graduate Degree Masters Business Admin | |
Gannon University | College/University | Undergraduate Degree | |
University of Massachusetts | College/University | Undergraduate Degree | |
University of Pavia | College/University | Undergraduate Degree | |
Robert Wood Johnson Medical School | College/University | Doctorate Degree | |
Abbott International LLC | Corporate Officer/Principal Sales & Marketing | ||
EryDel SpA
![]() EryDel SpA Medical SpecialtiesHealth Technology EryDel SpA offers medical research. It develops drugs and diagnostics delivered through human red blood cells via a medical device technology. The company was founded by Luigia Rossi and Mauro Magnani in 2007 and is headquartered in Bresso, Italy. | Medical Specialties | Director/Board Member | |
Crescendo Biologics Ltd.
![]() Crescendo Biologics Ltd. Miscellaneous Commercial ServicesCommercial Services Crescendo Biologics Ltd. engages in the development of new medicines based on antibody fragment technology. Its products in pipeline in dermatology include CB001, a transformational Humabody-based topical biologic for psoriasis which combines exceptional activity against a validated target with a topical route of delivery to avoid systemic side effects. The firm?s oncology products in pipeline include Humabody Multi-Specific T-Cell Engagers, Humabody Antibody Drug Conjugates and Immune Checkpoint Inhibitors. The company was founded by Michael Anthony Romanos, David Rayll Brown and John Bradshaw on November 13, 2007 and is headquartered in Cambridge, the United Kingdom. | Miscellaneous Commercial Services | Director/Board Member | |
MISSION Therapeutics Ltd.
![]() MISSION Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology MISSION Therapeutics Ltd. develops small molecule drugs targeting enzymes involved in cancer and other diseases. It focuses on selectively targeting deubiquitylating enzymes to treat cancer, neurodegenerative and other diseases. The company was founded by Stephen Jackson Philip, Xavier Jacq, Niall M. B. Martin and Keith Menear in 2011 and is headquartered in Cambridge, the United Kingdom. | Pharmaceuticals: Major | Director/Board Member | |
Hookipa Biotech AG
![]() Hookipa Biotech AG Medical SpecialtiesHealth Technology Hookipa Biotech AG develops new generation prophylactic and therapeutic vaccines. The firm’s Vaxwave technology is a novel immunotherapy platform using a replication-defective viral vector for the prevention and treatment of cancer and infectious diseases. The company was founded by Lukas Flatz, Andreas Bergthaler, Rolf M. Zinkernagel and Daniel Pinschewer in July 2011 and is headquartered in Vienna, Austria. | Medical Specialties | Director/Board Member | |
NYU Langone Health
![]() NYU Langone Health Packaged SoftwareTechnology Services NYU Elaine A. & Kenneth G. Langone Medical Center provides health care services. It offers treatments for bone, joint, and muscle disorders; brain and nervous system disorders cancers, tumors and blood disorders; genetic and chromosomal disorders and immune system disorders. The company was founded in 1841 and is headquartered in New York, NY. | Packaged Software | Corporate Officer/Principal | |
REVO BIOLOGICS INC | Biotechnology | Corporate Officer/Principal | |
Rotterdam School of Management | College/University | Masters Business Admin | |
Inotrem SA
![]() Inotrem SA BiotechnologyHealth Technology Inotrem SA specializes in the development of therapeutic approaches based on its proprietary TREM-1 platform. The firm focuses on the control of immune reactions in acute inflammatory diseases. The company was founded by Jean-Jacques Garaud, Marc Derive and Sebastien Gibot in 2013 and is headquartered in Paris, France. | Biotechnology | Director/Board Member | |
Corvidia Therapeutics, Inc.
![]() Corvidia Therapeutics, Inc. BiotechnologyHealth Technology Corvidia Therapeutics, Inc. is a biotechnology company focusing on cardiovascular therapies. It develops treatments for atherosclerotic cardiovascular disease, inflammation in chronic kidney diseases, and high triglyceride-induced acute pancreatitis. The company was founded by Michael H. Davidson, Rahul Kakkar, Matt Devalaraja, and Ram Aiyar in 2015 and is headquartered in Waltham, MA. | Biotechnology | Director/Board Member Corporate Officer/Principal | |
Breath Therapeutics GmbH
![]() Breath Therapeutics GmbH Pharmaceuticals: MajorHealth Technology Breath Therapeutics GmbH is a clinical stage biopharmaceutical company, which engages in the development of inhaled therapeutics for respiratory diseases. It offers drug device platform, which consists of liposomal drug-aerosol formulations and cutting-edge inhalation technology. The company was founded by Jens Stegemann, Gerhard Boerner, Oliver Denk, and Anne Burger in 2016 and is headquartered in Munchen, Germany. | Pharmaceuticals: Major | Director/Board Member | |
HotSpot Therapeutics, Inc.
![]() HotSpot Therapeutics, Inc. BiotechnologyHealth Technology HotSpot Therapeutics, Inc. develops new allosteric therapies with the ability to treat disease. The company was founded by Jonathan Montagu and Geraldine Harriman and is headquartered in Boston, MA. | Biotechnology | Director/Board Member | |
HOOKIPA PHARMA INC. | Biotechnology | Director/Board Member | |
GeneSpire Srl
![]() GeneSpire Srl BiotechnologyHealth Technology GeneSpire Srl is a holding company, which engages in the development of transformative gene therapies for patients with genetic diseases. The company was founded by Luigi Naldini and Alessio Cantone in March 2020 and is headquartered in Milan, Italy. | Biotechnology | Director/Board Member | |
Tenpoint Therapeutics Ltd.
![]() Tenpoint Therapeutics Ltd. BiotechnologyHealth Technology Tenpoint Therapeutics Ltd. is a British biotechnology company that specializes in developing engineered cell-based therapies and in vivo reprogramming to restore vision for individuals with degenerative ocular diseases. The company is based in Cambridge, UK and was founded in 2020. Tenpoint Therapeutics brings together experts who are shaping the regenerative ocular medicine revolution and the technologies that are driving it. The company's focus is on replacing diseased cells with healthy ones to permanently restore vision. Eddy Anglade has been the CEO of the company since 2023. | Biotechnology | Director/Board Member | |
GlycoEra AG
![]() GlycoEra AG BiotechnologyHealth Technology GlycoEra AG is a Swiss biotechnology company specializing in the development of novel biologics for various indications. The company is based in Schlieren, Switzerland, and the USA. The company utilizes its innovative customglycan platform to design, engineer, and develop medicines based on deep expertise in glycobiology. GlycoEra has raised over $49 million in a 2021 series A financing round co-led by 5AM Ventures, Sofinnova Partners, and Roche Venture Fund. The company was founded by Dominique Sirena, Amir Faridmoayer, and Veronica Gambillara Fonck. Ganesh Venkataraman Kaundinya has been the CEO of the company since 2020. | Biotechnology | Director/Board Member | |
Mablink Bioscience
![]() Mablink Bioscience Pharmaceuticals: MajorHealth Technology Mablink Bioscience is a biotechnology company based in Lyon, France that develops next-generation antibody-drug conjugates for the treatment of solid tumors. Mablink Bioscience's exclusive PSarlink™ platform is a unique stealth technology that "masks" the hydrophobicity of the cytotoxic drugs by adding a polysarcosine chain to the linker. The French company's pipeline is built on the topoisomerase-I inhibitor exatecan as a payload for current developments. Recently, the company announced the publication of a review article titled “Payload Diversification\: A Key Step in the Development of Antibody–Drug Conjugates” which reviews the history of the successes and failures in ADC payloads and takes a look at the new roads currently explored by the industry. The company was founded in 2018 by Warren Viricel and Jean-Guillaume Lafay, with Jean-Guillaume Lafay serving as CEO since then. | Pharmaceuticals: Major | Director/Board Member | |
Leucid Bio Ltd.
![]() Leucid Bio Ltd. Miscellaneous Commercial ServicesCommercial Services Leucid Bio Ltd. is a clinical-stage biotechnology company based in London, UK. The British company develops novel, lateral car cell therapies for the treatment of refractory cancers, with a focus on developing next-generation cell therapies for the benefit of individuals with hard-to-treat solid tumors. The company's operations are based at Guys Hospital, enabling them to maintain a patient-centric focus. Leucid's goal is to develop CAR-T therapies with more durable responses, improving treatment outcomes and saving the lives of patients with refractory cancers. Leucid was established to translate 20 years of Kings College research in the CAR-T field and is led by a highly experienced management team, including scientific founder John Maher. Filippo Joseph Petti has been the CEO of the company since 2023. | Miscellaneous Commercial Services | Director/Board Member | |
Alltrna
![]() Alltrna BiotechnologyHealth Technology Alltrna is a biotech company that uses AI/ML tools to learn the language of tRNA and develop programmable molecules with therapeutic potential. Alltrna was founded in 2018 by Flagship Pioneering and is based in Cambridge, MA. The company aims to correct diseases by advancing a single tRNA medicine to treat a wide range of diseases with the same underlying genetic mutation. The company's CEOs are Michelle C. Werner and Lovisa Afzelius. | Biotechnology | Director/Board Member | |
Jamanda Ltd.
![]() Jamanda Ltd. Financial ConglomeratesFinance Jamanda Ltd. is an investment holding British company founded in 2016. The private company is based in Grantham, UK. The company's main function is to hold investments. | Financial Conglomerates | Director/Board Member | |
FRAZIER LIFESCIENCES ACQUISITION CORPORATION | Pharmaceuticals: Major | Chief Operating Officer |
Statistik
International
Vereinigte Staaten | 28 |
Vereinigtes Königreich | 7 |
Italien | 6 |
Frankreich | 5 |
Schweiz | 4 |
Sektoral
Health Technology | 31 |
Consumer Services | 10 |
Finance | 7 |
Commercial Services | 3 |
Technology Services | 2 |
Operativ
Director/Board Member | 81 |
Corporate Officer/Principal | 41 |
Chairman | 26 |
Independent Dir/Board Member | 16 |
Undergraduate Degree | 14 |
Am stärksten vernetzte Beziehungen
Insiders | |
---|---|
David Mott | 45 |
Graziano Seghezzi | 26 |
Christian Schade | 18 |
Holger Liepmann | 14 |
George F. Horner | 12 |
Douglas Kling | 12 |
James Miller | 12 |
Matthew McAviney | 9 |
Kevin Rooney | 9 |
Ramona M. Lloyd | 8 |
Timothy J. Maines | 7 |
Daniel Courchesne | 6 |
Aled Williams | 5 |
Linda Peters | 5 |
Jonathan Peskoff | 3 |
- Börse
- Insiders
- Bernardus MacHielse
- Unternehmensverbindungen